DescriptionGCA has clearly 2 aspects; the first is about what is going on in the vessel wall, which can be detrimental in case of sight loss and the second are the systemic signs and symptoms.
A major problem of course is that present treatment only partly targets the vessel wall (Maleszewski/ Weyand paper) and also systemic signs and symptoms are only partly resolved or replaced by side effects of glucocorticoids.
My talk focusses on the peripheral blood compartment ( B-cells, T-cells (presently analyzed) and monocytes) before treatment and during follow up.
1 van Sleen Y, Wang Q, van der Geest KSM, Westra J, Abdulahad WH, Heeringa P, Boots AMH, Brouwer E. Involvement of Monocyte Subsets in the Immunopathology of
Giant Cell Arteritis. Sci Rep. 2017 Jul 26;7(1):6553. doi: 10.1038/s41598-017-06826-4. PubMed PMID: 28747747; PubMed Central PMCID: PMC5529580.
2. Graver JC, Sandovici M, Diepstra A, Boots AMH, Brouwer E. Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media
of temporal arteries. Ann Rheum Dis. 2017 Jun 24. pii: annrheumdis-2017-211860. doi: 10.1136/annrheumdis-2017-211860. [Epub ahead of print] PubMed PMID: 28647683.
3. van der Geest KS, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, Roffel MP, Roozendaal C, Kluin PM, Bos NA, Boots AM, Brouwer E. Disturbed B cell
homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014 Jul;66(7):1927-38. doi: 10.1002/art.38625. PubMed PMID:
|Periode||15-mrt-2018 → 17-mrt-2018|
|Gehouden op||The Mayo Clinic School of Continuous Professional Development and course directors, Drs. Kenneth J. Warrington, Eric L. Matteson and Bhaskar Dasgupta, United States|
|Mate van erkenning||International|